As marketing strategy consultants we are often called upon to look at the market opportunity in the United states for a company, a new drug or indication.
In order to do this it’s necessary to keep on top of the regulatory and reimbursement challenges that pharmaceutical and biotechnology companies face in the U.S. market.
Healthcare reform is a topic of active debate, especially with the passing of the Affordable Care Act (ACA) by Congress. Pieter Droppert on Biotech Strategy Blog looks at what we can learn two years after healthcare reform took place in Massachusetts.
The findings are interesting, access to insurance coverage is not the same as access to healthcare, and the spiraling costs remain the biggest challenge that has to be overcome. You can read more on Biotech Strategy Blog.